Citi has reiterated a Buy rating on PB Fintech with a target price of ₹2,185, citing robust growth momentum in the company’s retail health insurance business.
The brokerage expects PB Fintech to post >65% YoY growth in retail health insurance new business this quarter, providing greater visibility on future profitability.
Citi also highlighted that pricing rationality is improving across POSP (Point of Sale Persons) platforms, with business activity picking up at Paisabazaar, including PB Connect.
With recent market consolidation in POSP (through mergers among top players) and an anticipated listing of another large player, Citi believes industry discipline on pricing will improve further. Notably, POSP contributed 25–30% to FY2025 consolidated revenue for PB Fintech.
Disclaimer: The views and target prices mentioned in this article are as stated by Citi. They do not represent the opinions or recommendations of this publication. Readers are advised to consult their financial advisors before making any investment decisions.
